Special Update – Ziopharm (ZIOP) – 3 Patients Die In The IL-12 Trial

Ziopharm

BIOINVEST BREAKING NEWS – Special Update – Ziopharm (ZIOP) – 3 Patients Die In The IL-12 Trial. ZIOP is down sharply this morning (7/15) on the report that three patients have died in their ongoing multicenter Phase I trial of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.